核查意见 华泰联合证券有限责任公司关于 京东方华灿光电股份有限公司 公司已对募集资金进行专户存储管理，公司及京东方华灿光电（广东）有限 公司（以下简称"全资子公司"）与存放募集资金的商业银行、保荐机构签订了 《募集资金三方监管协议/四方监管协议》。 二、募集资金投资项目基本情况 根据《2022 年度向特定对象发行股票并在创业板上市募集说明书（注册 稿）》，本次募集资金扣除发行费用后的净额拟全部用于 Micro LED 晶圆制造 1 核查意见 使用部分闲置募集资金临时补充流动资金的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为京东方华灿光电股份有限公司（以下简称"华灿光电"或"公司"或"上市 公司"）持续督导工作的保荐机构，根据《证券发行上市保荐业务管理办法》《深 圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》及《上市公司募集 资金监管规则》等相关规定，对华灿光电拟使用部分闲置募集资金临时补充流动 资金的相关事项进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《 ...

证券代码：300323 证券简称：华灿光电 公告编号：2025-038 京东方华灿光电股份有限公司 关于使用部分闲置募集资金临时补充流动资金的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 京东方华灿光电股份有限公司（以下简称"公司"）于 2025 年 7 月 23 日召开第六届董 事会第十五次会议、第六届监事会第十三次会议审议通过《关于使用部分闲置募集资金临时 补充流动资金的议案》，同意公司在保证募集资金项目的资金需求及募集资金使用计划正常进 行的前提下，使用不超过 50,000 万元部分闲置募集资金临时补充流动资金，使用期限为自董 事会审议通过之日起不超过 12 个月，到期后将归还到募集资金专用账户。现就使用部分闲置 募集资金临时补充流动资金的相关事项公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意京东方华灿光电股份有限公司向特定对象发行 股票注册的批复》（证监许可[2023]1442 号），公司向特定对象发行人民币普通股（A 股） 372,070,935.00 股，发行价格为 5.60 元/股，募集资金总额人民币 2,083, ...

证券代码：300323 证券简称：华灿光电 公告编号：2025-037 京东方华灿光电股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 华灿光电股份有限公司（以下简称"公司"）于 2020 年 12 月 08 日召开的第四届 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 京东方华灿光电股份有限公司（以下简称"公司"）于 2025 年 7 月 23 日召开第六届董 事会第十五次会议、第六届监事会第十三次会议审议通过《关于使用部分闲置募集资金进行 现金管理的议案》，同意公司及全资子公司京东方华灿光电（广东）有限公司（以下简称"全 资子公司"）在不影响募集资金投资项目正常实施的前提下，使用不超过人民币 10,000 万元 的闲置募集资金进行现金管理，使用期限自公司董事会审议通过之日起十二个月内有效，在 上述使用期限及额度范围内，资金可以循环滚动使用。保荐机构出具了无异议的核查意见， 该议案无需提交公司股东会审议。现就使用部分闲置募集资金进行现金管理的相关事项公告 如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意京东方华灿光电股份有限公司向 ...

证券代码：300323 证券简称：华灿光电 公告编号：2025-035 京东方华灿光电股份有限公司 1、审议通过《关于使用部分闲置募集资金进行现金管理的议案》 经审议，监事会认为：公司及全资子公司使用闲置募集资金进行现金管理，有利于 提高募集资金的使用效率，获得一定的投资收益，不会影响公司主营业务的正常开展和 募集资金投资项目的建设，不存在变相改变募集资金用途的行为，符合有关法律法规、 规范性文件的相关规定。公司监事会同意公司及全资子公司使用闲置募集资金进行现 金管理。 表决结果：赞成 3 票，反对 0 票，弃权 0 票。 第六届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、京东方华灿光电股份有限公司（以下简称"公司"）第六届监事会第十三次会议通 知于 2025 年 7 月 16 日以电话、邮件方式向全体监事送达。 2、本次监事会于 2025 年 7 月 23 日在公司会议室以现场会议方式召开，会议由监 事会主席俞信华先生主持。 3、本次监事会会议应到监事 3 名，实到监事 3 名。 4、本次监事会会议 ...

Core Viewpoint - The global display industry is entering a rebalancing phase, shifting from competition based on scale and market share to a focus on high profitability, high technology, and high added value [3]. Group 1: Industry Overview - The display industry is currently dominated by two core technologies: LCD and OLED, with Chinese companies, particularly BOE, leading the global LCD market [1]. - The demand structure for LCD is optimizing, with a significant trend towards larger TV sizes, while OLED is gaining traction in high-end segments, including foldable screens [3]. - Emerging display technologies, such as Mini/Micro LED, are expected to inject innovation and growth into the industry [3]. Group 2: Company Developments - BOE has introduced the "Screen IoT" strategy and the "N Curve" theory to drive its development, focusing on display technology, glass-based processing capabilities, and large-scale integrated intelligent manufacturing [3]. - The company has made significant progress in new business areas, including glass-based packaging and perovskite photovoltaic devices, with successful production milestones achieved [4]. - BOE's automotive display platform, BOE Precision Electronics, reported over 10 billion RMB in revenue last year, becoming the global leader in automotive display shipments [4]. Group 3: Financial Performance - In 2024, BOE achieved revenue of 198.38 billion RMB, a year-on-year increase of 13.66%, with a net profit of 5.32 billion RMB, up 108.97% [7]. - The display device business generated 165 billion RMB in revenue, maintaining the global lead in LCD shipments and ranking second in flexible OLED shipments [7]. - The gross margin for the display device business improved to 12.75%, an increase of over 4 percentage points from 2023 [7]. Group 4: Capital Strategy - BOE is shifting its capital strategy from scale expansion to shareholder value creation, with expectations of entering a profit improvement phase post-2025 [5]. - The company has initiated a three-year shareholder return plan, including stock buybacks and profit distribution, to enhance shareholder returns [7]. - Capital operations include mergers and acquisitions of quality assets and independent listings of innovative businesses to strengthen overall corporate capabilities [8].

Core Viewpoint - The panel industry in China is experiencing a recovery, with many companies reporting improved performance and reduced losses for the first half of 2025, despite facing challenges from external trade environments and declining terminal demand [1][3][6]. Group 1: Company Performance - Huaying Technology expects a net loss of 466 million to 486 million yuan for the first half of 2025, an improvement of 13.81% to 17.36% compared to a loss of 564 million yuan in the same period last year [3]. - BOE Technology and Huacan Optoelectronics forecast a reduced loss, with net profit expected to be between -150 million to -90 million yuan, reflecting a year-on-year increase of 39.13% to 63.48% [3][4]. - TCL Technology anticipates revenue of 82.6 billion to 90.6 billion yuan, a year-on-year growth of 3% to 13%, with net profit expected to be between 1.8 billion to 2 billion yuan, representing an increase of 81% to 101% [4][5]. Group 2: Market Trends - The overall TV market in China showed a slight increase in shipments, with a total of 1,662.5 million units shipped in the first half of 2025, a growth of only 1.4% year-on-year [7]. - The large-size LCD TV panel shipments in May 2025 reached 19.3 million units, a year-on-year decline of 7.5%, indicating a downward trend in demand [7]. - Despite the challenges, the trend towards larger screens is expected to continue, with predictions of over 2.4 million units in the ultra-large screen market by 2026 [8].

证券代码：300323 证券简称：华灿光电 公告编号：2025-032 京东方华灿光电股份有限公司 2025年半年度业绩预告 一、本期业绩预计情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况：预计净利润为负值 | 项 | 目 | 本报告期 | | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | | 亏损：15,000.00 | 万元– | 9,000.00 | 万元 | 亏损：24,642.35 | 万元 | | 扣除非经常性损 益后的净利润 | | 亏损：25,000.00 | 万元– | 19,000.00 | 万元 | 亏损：30,109.85 | 万元 | 二、与会计师事务所沟通情况 本期业绩预告相关财务数据为京东方华灿光电股份有限公司（以下简称"公司"） 财务部门初步测算的结果，未经注册会计师审计。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 三、业绩变动原因说明 报告期 ...

Market Overview - The Shanghai Composite Index is at 3377.32 points, above the six-month moving average, with a gain of 0.52% [1] - The total trading volume of A-shares today is 887.15 billion yuan [1] Stocks Performance - A total of 335 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Haixin Energy Technology (15.52%) - Tengyuan Cobalt Industry (14.25%) - Aerospace Development (9.29%) [1] Detailed Stock Data - The following stocks have shown notable performance: - Haixin Energy Technology: Today's gain of 20.06%, turnover rate of 7.04%, latest price at 3.71 yuan [1] - Tengyuan Cobalt Industry: Today's gain of 14.50%, turnover rate of 15.34%, latest price at 54.57 yuan [1] - Aerospace Development: Today's gain of 9.94%, turnover rate of 6.84%, latest price at 7.96 yuan [1] - Other stocks with lower deviation rates include: - Jihigh Development - Guosheng Technology - Jiangfeng Electronics, which have just crossed the six-month moving average [1]

Core Points - The Shanghai Composite Index closed at 3365.07 points, below the five-day moving average, with a change of 0.15% [1] - The total trading volume of A-shares reached 683.87 billion yuan [1] - A total of 820 A-shares have prices that surpassed the five-day moving average [1] Individual Stock Performance - SanDe Technology (300515) had a price increase of 19.98% with a deviation rate of 13.78% from the five-day moving average [2] - HaiXin Energy Technology (300072) saw a price increase of 20.06% with a deviation rate of 12.77% [2] - QiLin Information Security (688152) experienced a price increase of 13.18% with a deviation rate of 9.66% [2] - Other notable stocks include TengYuan Cobalt (301219) with a 14.39% increase and a 9.34% deviation rate, and Jiangsu BoYun (301003) with a 14.60% increase and a 9.11% deviation rate [2]

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]